Emi Taniguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emi Taniguchi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Kazuyo Yoshida
3 shared publicationsMami Kurata
3 shared publications- Masahiro Kuno
Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
3 shared publications - Meiko Nishimura
Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
3 shared publications - Takayuki Kobayashi
Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
3 shared publications - Takayuki Ueno
Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
3 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Elsevier in The Breast
- Vol. 91
Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)
- 12 November 2026
- Published by Elsevier in The Breast
- Vol. 91
Open AccessTime to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)
- Open Access
- 11 September 2026
- Published by Elsevier in SSRN Electronic Journal
Time to Maximal Response of Trastuzumab Deruxtecan in Patients with HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study (TRACE)
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated transformative efficacy in HER2-positive metastatic breast cancer (MBC), and induction–maintenance strategies with T-DXd are under investigation to optimize the treatments. Understanding the time to maximal response (TTMR) is important for optimizing induction duration. However, real-world data on TTMR with T-DXd remain limited.Methods: TRACE is a multicenter, retrospective observational study. Patients with histologically confirmed HER2-positive MBC who received T-DXd between 2020 and 2025 were eligible. The primary endpoint was TTMR, defined as the time from T-DXd initiation to the nadir of target lesion sum of diameters, assessed according to RECIST v1.1. Patients with progressive disease as best overall response, stable disease without tumor shrinkage, or no evaluable target lesions were excluded.Results: Of 125 patients identified, 93 were eligible for the primary analysis. The median age was 60 years; 62% had hormone receptor-positive disease, and 66% received T-DXd in the third line or later. The median TTMR was 4.57 months (95% CI: 3.73–5.60). No significant difference in TTMR was observed by subgroups. Best overall response was CR in 9%, PR in 74%, and SD in 17%. Spider plot analysis showed a median tumor burden change of −2.7% beyond 18 weeks.Conclusions: In this real-world multicenter cohort, T-DXd achieved maximal tumor shrinkage at a median of 4.57 months in patients with HER2-positive MBC. Tumor burden change beyond 18 weeks was minimal at the population level, suggesting limited additional benefit from continued T-DXd. These findings may inform future maintenance strategies in HER2-positive MBC.
- 11 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTime to Maximal Response of Trastuzumab Deruxtecan in Patients with HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study (TRACE)
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated transformative efficacy in HER2-positive metastatic breast cancer (MBC), and induction–maintenance strategies with T-DXd are under investigation to optimize the treatments. Understanding the time to maximal response (TTMR) is important for optimizing induction duration. However, real-world data on TTMR with T-DXd remain limited.Methods: TRACE is a multicenter, retrospective observational study. Patients with histologically confirmed HER2-positive MBC who received T-DXd between 2020 and 2025 were eligible. The primary endpoint was TTMR, defined as the time from T-DXd initiation to the nadir of target lesion sum of diameters, assessed according to RECIST v1.1. Patients with progressive disease as best overall response, stable disease without tumor shrinkage, or no evaluable target lesions were excluded.Results: Of 125 patients identified, 93 were eligible for the primary analysis. The median age was 60 years; 62% had hormone receptor-positive disease, and 66% received T-DXd in the third line or later. The median TTMR was 4.57 months (95% CI: 3.73–5.60). No significant difference in TTMR was observed by subgroups. Best overall response was CR in 9%, PR in 74%, and SD in 17%. Spider plot analysis showed a median tumor burden change of −2.7% beyond 18 weeks.Conclusions: In this real-world multicenter cohort, T-DXd achieved maximal tumor shrinkage at a median of 4.57 months in patients with HER2-positive MBC. Tumor burden change beyond 18 weeks was minimal at the population level, suggesting limited additional benefit from continued T-DXd. These findings may inform future maintenance strategies in HER2-positive MBC.